The EXCEED-ET trial has quantified the therapeutic impact of ropeginterferon alfa-2b-njft in essential thrombocythemia, with 61% of patients achieving complete blood count normalization by month 12. This efficacy metric proves particularly significant given the genetic heterogeneity of the patient population studied.
When stratified by mutation type, response rates demonstrated clinical consistency: JAK2-mutated patients achieved 65% complete hematological response, CALR-mutated patients reached 60%, and MPL-mutated patients attained 50%—demonstrating robust efficacy across all major driver mutation categories. This statistical uniformity addresses a critical clinical challenge in essential thrombocythemia management, where treatment responses have historically varied based on genetic background. The median 18-month follow-up period provides meaningful durability data supporting sustained treatment benefit. These findings suggest that ropeginterferon may offer a mutation-agnostic therapeutic approach for this rare hematologic malignancy.
Read the full article on GMJ Newsroom.
Was this article helpful?
